Issue link: https://viewer.e-digitaledition.com/i/512409
illness, depression would be over- or under-diagnosed." Clinicians have long recognized the limi- tations of existing diagnostic approaches. For instance, addressing diagnosis of depression among patients with advanced metastatic cancer, a September 2000 article in Postgraduate Medical Journal noted: "[U]p to 80% of the psychological and psychiatric morbidity which develops in cancer patients goes unrecognised and untreated. One of the main diffi culties in establishing a diagnosis of an illness where there are no biological markers, physical signs, or diagnostics tests is deciding what can be called 'appropriate sadness' as patients approach the end of life and what is a depressive illness." Predictive Potential The newly developed blood test mea- sures the level of nine RNA markers that were found to be significantly different at baseline between participants in the control group and those who had previously been independently diag- nosed with MDD. Identifying the range within which RNA markers typically register in healthy patients enables psychiatrists to diagnose MDD with the blood test — similar to diagnosing high cholesterol or diabetes. Over an 18-week period, depressed participants in the study underwent cognitive behavioral therapy (CBT) sessions in person and by phone. CBT is often used along with medications and, in severe cases, electroconvulsive therapy. Researchers tracked the RNA marker levels throughout and found that changes in three markers correlated with positive response to therapy. Some patients did not respond to CBT, a nd resea rchers ret ur ned to baseline RNA marker levels to evalu- ate whether there was evidence that the test could also serve as a predictor of therapeutic success. They found that it did, as patients who responded positively to CBT had a distinct pattern of marker levels. The new blood test may offer psy- chiatrists the opportunit y to more individually craft treatment plans for patients with MDD and potentially increase the efficacy of therapy. Further Applications In addition, the test's evaluative capabili- ties might reach beyond CBT success rates. Three RNA markers are concentrated in a specifi c way in depressed patients — regardless of the resolution of MDD after therapy. " T h r e e b l o o d m a r k e r s s h o w e d depressed levels in some of the patients, even after they remitted," Redei says. "That suggested that these markers show susceptibility to depression, and that patients showing these patterns may likely have another episode of MDD. [These patients] should be closely moni- t ore d , a n d p erh a p s t re a t e d w it h ps ychot herapy or a nt idepressa nt s, as is frequently done in patients with recurrent depression. However, if these markers are confi rmed, they could iden- tify patients with susceptibility even before the next episode occurs." Redei, who previously developed a similar blood test to identify MDD in teenagers, expanded the demographics in this study, enrolling patients between 23 and 83 years old. The three markers that differed between control participants and patients with MDD in the team's current study also differed in the study geared to teens, confi rming the role of the markers in pathological processes associated with depressed moods. Redei and her team plan to expand study populations and determine whether the test can differentiate between uni- polar MDD and bipolar depression. ■ "Depression is an illness, just like other illnesses. It can be objectively diagnosed. A non-psychiatrist can be helped by this objective test as well, as we know that depressed patients are seeing more physicians more times than non-depressed patients." — Eva E. Redei, PhD, David L. Stein Professor of Psychiatry in the Department of Psychiatry and Behavioral Sciences at Northwestern University's Feinberg School of Medicine M D N E W S . CO M ■ MD NEWS Eastern Pennsylvania/NW New Jersey | 1 1

